History & Overview Annual Report President's Pages Center News Community Affairs
Make a Gift Cycle for Survival Fred's Team Rock & Run on the River Yankees Universe Fund Thomas Blake Sr. Memorial Research Fund Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck CELEBRATIONS
Press Releases In the News Information for Journalists News@MSKCC
Manhattan New Jersey Long Island Westchester
Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days IS Careers Job Search & Apply Online
Making an Appointment

Paul B. Chapman, MD

Paul B. Chapman
Paul B. Chapman, MD
My overall goal is to develop new and effective treatments for metastatic melanoma. To do this, I -- along with my colleagues on the Melanoma and Sarcoma Service -- am focusing on several lines of research.
  • Immune attack
    We know the immune system is potentially powerful and capable of eliminating foreign tissue efficiently. It has been difficult to harness this power against cancer because the immune systems does not recognize cancer cells as foreign. We are conducting trials with monoclonal antibodies such as ipilimumab to activate the immune system against melanoma. Also, we are working to develop vaccines against melanoma that we hope can be used to direct the patient’s immune system against residual melanoma cells.
  • Drugs to target the genetic mutations in melanoma cells.
    We have learned that two biochemical pathways -- the MAPK and the AKT pathways -- are critical for melanoma survival and that melanoma cells usually have mutations that result in these pathways being stuck in the “on” mode. We are currently conducting clinical trials with new drugs designed to block one or both of these pathways. This is the beginning of personalized medicine, allowing us to select specific drugs based on the genetics of the individual patient's individual.
  • Better use of chemotherapy.
    It is commonly said that chemotherapy does not work in melanoma, but in fact, it clearly does work in some patients. I am studying which patients respond to chemotherapy so that, in the future, we can predict which patients have melanomas that will respond. Knowing what makes a melanoma sensitive to chemotherapy may teach us how to convert a resistant tumor to a sensitive one.
    Phone
    646-888-2378

    Education
    MD, Cornell University Medical College

    Residencies
    University of Chicago Hospitals and Clinics

    Fellowships
    Memorial Sloan-Kettering Cancer Center

    Board Certifications
    Internal Medicine; Medical Oncology

    Clinical Expertise
    Melanoma; Immunotherapy; Cancer Vaccines; Novel Targeted Therapy for Melanoma; Chemotherapy

    Department & Service


  • Bookmark and SharePrintEmail This Page